Dear Colleagues,
Although carcinoma of the ovary affects women worldwide, the only effective treatment for ovarian neoplasia is limited to improving the patients’ survival and quality of life. Conventional cytotoxic agents have been at the center of treatment for more than three decades, but with disappointing clinical benefits. Hence, there is an urgent need for novel anticancer drugs to treat ovarian cancer patients. Recently, there has been hope for patients with specific germline mutations to receive targeted therapy. Clinical data reveal the effectiveness of these targeted drugs in fighting ovarian cancer. This special issue will highlight the discovery of novel targeted treatments for ovarian cancer, and is not limited to re-purposed drugs from other medication entities. In addition, this special issue will focus on three-dimensional and animal models to validate the efficacy of targeted drugs. Submissions describing the combination of conventional cytotoxic drugs with novel targeted drugs are encouraged, as well as those reporting the proteomic and phospho-proteomic profiles, both in vitro and in vivo, of ovarian cancer.
Dr. Kenny Chitcholtan
Guest Editor
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1500 USD. Submitted manuscripts should be well formatted in good English.